Skip to Content
Merck
All Photos(1)

Documents

676495

Sigma-Aldrich

VEGF Inhibitor, V1

The VEGF Inhibitor, V1 controls the biological activity of VEGF. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Synonym(s):

VEGF Inhibitor, V1, ATWLPPR

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C40H61N11O9
Molecular Weight:
839.98
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥95% (HPLC)

form

lyophilized solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
desiccated (hygroscopic)

color

white

solubility

DMSO: 5 mg/mL

shipped in

ambient

storage temp.

2-8°C

General description

An NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.
An NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.

Biochem/physiol Actions

Cell permeable: no
Primary Target
Specifically competes against VEGF165 binding to recombinant NRP-1
Product does not compete with ATP.
Reversible: no
Target IC50: 60 µM for specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Sequence

H-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH

Other Notes

Starzec, A., et al. 2006. Life Sci.79, 2370.
Binetruy-Tournaire, R., et al. 2000. EMBO J.19, 1525.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service